Soligenix Inc, (SNGX)
$3.5
Live
Performance
- $3.50$3.88$3.50
0.0%
Downside
Day's Volatility :9.79%
Upside
9.79%
- $1.83$32.00$3.50
47.71%
Downside
52 Weeks Volatility :94.28%
Upside
89.06%
Returns
| Period | Soligenix Inc, | Index (Russel 2000) |
|---|---|---|
3 Months | -24.95% | 0.0% |
6 Months | -40.47% | 0.0% |
1 Year | -53.99% | 0.0% |
3 Years | -98.43% | -23.0% |
Highlights
Market Capitalization | 8.3M |
Book Value | $2.25 |
Earnings Per Share (EPS) | -8.0 |
PEG Ratio | -1.52 |
Wall Street Target Price | 22.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -74495.09% |
Return On Assets TTM | -41.04% |
Return On Equity TTM | -152.02% |
Revenue TTM | 494.6K |
Revenue Per Share TTM | 0.62 |
Quarterly Revenue Growth YOY | -98.9% |
Gross Profit TTM | 95.6K |
EBITDA | -7.8M |
Diluted Eps TTM | -8.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.99 |
EPS Estimate Next Year | -5.06 |
EPS Estimate Current Quarter | -1.77 |
EPS Estimate Next Quarter | -1.9 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 542.86%
Technicals Summary
Sell
Neutral
Buy
Soligenix Inc, is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Soligenix Inc, | -0.08% | -40.47% | -53.99% | -98.43% | -98.21% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Soligenix Inc, | NA | NA | -1.52 | -5.99 | -1.52 | -0.41 | NA | 2.25 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Soligenix Inc, | Buy | $8.3M | -98.21% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Soligenix Inc,
Decreasing Revenue
Revenue is down for the last 3 quarters, 244.81K → 2.34K (in $), with an average decrease of 75.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -1.91M → -1.64M (in $), with an average increase of 16.5% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 137.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 143.2%
Institutional Holdings
Armistice Capital, LLC
3.51%Old National Bancorp
0.44%UBS Group AG
0.27%Tower Research Capital LLC
0.16%Plante Moran Financial Advisors LP
0.01%Morgan Stanley - Brokerage Accounts
0.01%
Company Information
soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Organization | Soligenix Inc, |
Employees | 13 |
CEO | Dr. Christopher J. Schaber Ph.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.50
-9.44%
Invesco Bulletshares 2025 Hi
$3.50
-9.44%
Schwab International Dividend Equity Etf
$3.50
-9.44%
Blockchain Coinvestors Acquisition Corp.
$3.50
-9.44%
Allgiant Travel Company
$3.50
-9.44%
Rogers Corp
$3.50
-9.44%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.50
-9.44%
Iheartmedia
$3.50
-9.44%
Lightpath Technologies Inc
$3.50
-9.44%